****

**TABLE OF CONTENTS**

[1. REPORT OVERVIEW 14](#_Toc66530185)

[1.1 Statement of the Report 14](#_Toc66530186)

[1.2 Target Demographic 16](#_Toc66530187)

[1.3 Report Sources 17](#_Toc66530188)

[1.4 Purpose of the Report 17](#_Toc66530189)

[1.4.1 Survey Recent Developments in Exosome Industry 17](#_Toc66530190)

[1.4.2 Provide a “Snapshot” of Global Exosome Market 17](#_Toc66530191)

[1.4.3 Assess Opportunities for Commercialization 18](#_Toc66530192)

[1.4.4 Identify Major Market Players and Assess the Competive Environment 18](#_Toc66530193)

[1.4.5 Identify Existing and Emerging Trends 18](#_Toc66530194)

[1.4.6 Identify Critical Opportunities and Threats within the Exosome Market 18](#_Toc66530195)

[1.5 Executive Summary 19](#_Toc66530196)

[1.6 Introduction 20](#_Toc66530197)

[2. EXOSOMES: AN OVERVIEW 21](#_Toc66530198)

[2.1 Structure of an Exosome 23](#_Toc66530199)

[2.1.1 Molecular Content of Exosomes 24](#_Toc66530200)

[2.1.1.1 Proteins in Exosomes 24](#_Toc66530201)

[2.1.1.2 Lipid Cargo in Exosomes 26](#_Toc66530202)

[2.1.1.3 Nucleic Acids in Exosomes 27](#_Toc66530203)

[2.1.1.4 Components of Membrane and Lumen of Exosomes 27](#_Toc66530204)

[2.2 Engineered Exosomes 28](#_Toc66530205)

[2.3 Functions of Exosomes 30](#_Toc66530206)

[2.3.1 Pivotal Role of Exosomes 30](#_Toc66530207)

[2.4 Adaptability to Engineering 30](#_Toc66530208)

[2.5 Differences between Exosome Therapy and Cell Therapy 31](#_Toc66530209)

[2.6 Sources of Exosomes for Research and Clinical Applications 32](#_Toc66530210)

[2.7 The Good Sides of Exosomes 33](#_Toc66530211)

[2.8 The Bad Side of Exosomes 34](#_Toc66530212)

[2.9 The Shift from Cell Therapy to Exosome Therapy 34](#_Toc66530213)

[3. EXOSOME RESEARCH 36](#_Toc66530214)

[3.1 To Inhibit Disease-Derived Exosomes 36](#_Toc66530215)

[3.1.1 To Use Exosomes as Therapeutic Platforms 36](#_Toc66530216)

[3.1.2 To Use Exosomes as Carriers of Genes in Gene Therapy 37](#_Toc66530217)

[3.1.3 To Use Exosomes as Drug Delivery Carriers 37](#_Toc66530218)

[3.2 Technologies for Exosome Isolation in Exosome Research 37](#_Toc66530219)

[3.2.1 Common Isolation Methods in Exosome Research 38](#_Toc66530220)

[3.3 Quality Control (QC) of Exosomes in Exosome Research 38](#_Toc66530221)

[3.4 Bioimaging Modalities used in Exosomes Research 39](#_Toc66530222)

[3.5 Labeling Methods used in Exosome Research 40](#_Toc66530223)

[3.6 Fluorescent Dyes used in Labeling Exosomes 42](#_Toc66530224)

[3.7 Common Methods to Remove Unlabelled Probes 43](#_Toc66530225)

[3.8 Determination of Exosome Dose in Exosome Research 44](#_Toc66530226)

[3.9 Routes of Exosome Administration 44](#_Toc66530227)

[3.10 Characterization of Exosomes in Research 45](#_Toc66530228)

[3.11 Scientific Publications on Exosomes 46](#_Toc66530229)

[3.11.1 Trend of Global Publications 46](#_Toc66530230)

[3.11.2 PubMed Publications on Exosome DNA as Diagnostics 47](#_Toc66530231)

[3.11.3 PubMed Publications on Exosome RNA as Diagnostics 48](#_Toc66530232)

[3.11.4 PubMed Publications on Exosome Proteins as Diagnostics 49](#_Toc66530233)

[3.11.5 PubMed.gov Publications on Exosomes Derived from Stem Cells 50](#_Toc66530234)

[3.11.6 PubMed.gov Publications on Exosome-based Diagnostics 51](#_Toc66530235)

[3.11.7 PubMed.gov Publications on Exosome-based Therapeutics 52](#_Toc66530236)

[3.11.8 PubMed.gov Publications on Exosomes for Cancer Diagnosis 53](#_Toc66530237)

[3.11.9 PubMed.gov Publications on Exosomes for Pregnancy Disorders Diagnosis 54](#_Toc66530238)

[3.12 Trends in Exosome Research Publications 55](#_Toc66530239)

[4. EXOSOMES: CLINICAL TRIALS LANDSCAPE 56](#_Toc66530240)

[4.1 Sources of Exosomes used in Clinical Trials 57](#_Toc66530241)

[4.2 Studies using Anti-tumor Antigens 57](#_Toc66530242)

[4.3 Studies using Cytotoxic Drugs against Cancer 57](#_Toc66530243)

[4.4 Recruitment Status of Ongoing Exosome-based Clinical Trials 58](#_Toc66530244)

[4.5 Study Designs 58](#_Toc66530245)

[4.6 Study Phases 59](#_Toc66530246)

[4.7 Funding Types 60](#_Toc66530247)

[4.8 Exosome Clinical Trials by Geography 61](#_Toc66530248)

[4.9 Exosome-based Clinical Trials by Application 61](#_Toc66530249)

[4.10 Clinical Trials Involving MSC-Derived Exosomes 62](#_Toc66530250)

[4.11 Clinical Trials involving Drug-Loaded Exosomes 63](#_Toc66530251)

[5. CURRENT STATUS OF EXOSOME MANUFACTURING 65](#_Toc66530252)

[5.1 Production of Exosomes from Cell Cultures 65](#_Toc66530253)

[5.2 Production Formats 66](#_Toc66530254)

[5.2.1 Large Scale Production 66](#_Toc66530255)

[5.3 Exosome Manufacturing Companies 67](#_Toc66530256)

[5.4 Companies Offering Exosome-Related Services 69](#_Toc66530257)

[6. CURRENT STATUS OF EXOSOME INDUSTRY 71](#_Toc66530258)

[6.1 Exosomes: The Current Focus of Stem Cell Companies 71](#_Toc66530259)

[6.2 Clinical Applications of Exosomes 72](#_Toc66530260)

[6.2.1 Diagnostic Applications 73](#_Toc66530261)

[6.2.1.1 ExoDx Prostate IntelliScore (EPI) Test 74](#_Toc66530262)

[6.2.1.2 Guardant360 CDx 74](#_Toc66530263)

[6.2.2 Clinical Trials Focusing on Exosome Diagnostics 75](#_Toc66530264)

[6.3 Therapeutic Applications 76](#_Toc66530265)

[6.3.1 Promising Exosome-based Therapeutic Candidates 77](#_Toc66530266)

[6.3.1.1 AB 126 77](#_Toc66530267)

[6.3.1.2 AGLE-102 78](#_Toc66530268)

[6.3.1.3 AVA-201 78](#_Toc66530269)

[6.3.1.4 AVA-202 78](#_Toc66530270)

[6.3.1.5 AZ 001 78](#_Toc66530271)

[6.3.1.6 CAP-2003 79](#_Toc66530272)

[6.3.1.7 exolL-12 79](#_Toc66530273)

[6.3.1.8 ExoPr0 79](#_Toc66530274)

[6.3.1.9 exoSTING 80](#_Toc66530275)

[6.3.1.10 exoSTING 80](#_Toc66530276)

[6.3.1.11 Plexaris 80](#_Toc66530277)

[6.3.1.12 UNEX-42 81](#_Toc66530278)

[6.3.1.13 Unexisome 81](#_Toc66530279)

[6.3.1.14 VT-105 81](#_Toc66530280)

[6.4 Addressable Diseases by Exosome Therapeutics 81](#_Toc66530281)

[6.5 Cell-Free Vaccine Development 82](#_Toc66530282)

[6.6 Current Status of Clinical Trials involving Exosomes 83](#_Toc66530283)

[6.7 The Entry of Designer Exosomes 86](#_Toc66530284)

[6.8 NIH Funding for Exosome Research 87](#_Toc66530285)

[6.9 Deals and Fund Raising in Exosome Space 88](#_Toc66530286)

[6.9.1 Partnerships in Exosome Industry 88](#_Toc66530287)

[6.9.2 Venture Capital Funding in Exosome Industry 90](#_Toc66530288)

[6.9.3 Acquisition Deals 92](#_Toc66530289)

[6.10 Prominent Exopreneurs in the Industry 93](#_Toc66530290)

[6.10.1 ArunA Biomedical 93](#_Toc66530291)

[6.10.2 Capricor Therapeutics 93](#_Toc66530292)

[6.10.3 Codiak Biosciences 94](#_Toc66530293)

[6.10.4 Evox Therapeutics 94](#_Toc66530294)

[6.10.5 Exosome Diagnostics, Inc. 94](#_Toc66530295)

[6.10.6 Exocyte Therapeutics 95](#_Toc66530296)

[6.10.7 Kimera Labs 95](#_Toc66530297)

[6.10.8 NanoSomiX 95](#_Toc66530298)

[6.11 Categories of Exosome Companies 96](#_Toc66530299)

[6.12 Major Companies Holding Exosome Patents 97](#_Toc66530300)

[6.13 Future Perspectives 98](#_Toc66530301)

[7. EXOSOME ISOLATION APPROACHES 100](#_Toc66530302)

[7.1 Differential Ultracentrifugation 100](#_Toc66530303)

[7.2 Gradient Density Ultracentrifugation 101](#_Toc66530304)

[7.3 Ultrafiltration & Sequential Ultrafiltration 102](#_Toc66530305)

[7.4 Size-exclusion Chromatography 102](#_Toc66530306)

[7.5 Polymer Precipitation 103](#_Toc66530307)

[7.6 Immunoaffinity Capture 104](#_Toc66530308)

[7.7 Microfluidics-Based Techniques 104](#_Toc66530309)

[7.7.1 Active and Passive Methods of Microfluidics Platforms 105](#_Toc66530310)

[7.8 Commercially Available Exosome Isolation Kits 108](#_Toc66530311)

[7.8.1 Comparison of Currently Used Methods of Exosome Isolation 109](#_Toc66530312)

[7.8.2 Quality of Exosomes Isolated by Different Methods 110](#_Toc66530313)

[7.8.3 Summary of Different Isolation Methods on Current use 110](#_Toc66530314)

[7.9 Characterization of Exosomes 112](#_Toc66530315)

[7.9.1 Size and Shape 112](#_Toc66530316)

[7.9.2 Molecular Profiling 112](#_Toc66530317)

[7.9.2.1 Proteomics and Lipidomics 112](#_Toc66530318)

[7.9.2.2 Genomics 113](#_Toc66530319)

[7.9.3 Microscopy and Nanoscopy for Exosome Imaging 113](#_Toc66530320)

[7.9.3.1 Direct Post-Isolation Labeling for Imaging 113](#_Toc66530321)

[7.9.4 Approaches for Exosome Analysis of Gene and Protein Biomarkers 113](#_Toc66530322)

[7.9.5 Emerging Optical Technologies for Exosome Analysis 114](#_Toc66530323)

[7.9.6 Emerging Electrochemical and Electromechanical Approaches 118](#_Toc66530324)

[8. EXOSOME ENGINEERING: A NEW PLATFORM 120](#_Toc66530325)

[8.1 Exosome Engineering Approaches 120](#_Toc66530326)

[8.1.1 Parental Cell-Based Exosome Engineering 121](#_Toc66530327)

[8.1.2 Direct or Post-Isolation Exosome Engineering Approach 121](#_Toc66530328)

[8.1.2.1 Loaded and Displayed Molecules in Direct Exosome Engineering 122](#_Toc66530329)

[8.2 Clinical Applications of Designer Exosomes 123](#_Toc66530330)

[8.2.1 Targeted Designer Exosomes 123](#_Toc66530331)

[8.2.2 Anti-Cancer Designer Exosomes 124](#_Toc66530332)

[8.2.3 Regenerative Designer Exosomes 124](#_Toc66530333)

[8.3 Companies Developing Engineered Exosome-Based Therapeutics 124](#_Toc66530334)

[9. MSC-DERIVED EXOSOMES IN REGENERATIVE MEDICINE 125](#_Toc66530335)

[9.1 Cardiovascular Diseases 126](#_Toc66530336)

[9.2 Kidney Diseases 127](#_Toc66530337)

[9.3 Liver Diseases 128](#_Toc66530338)

[9.4 Wound Healing 129](#_Toc66530339)

[9.5 Select MSC Exosome-Based Clinical Trials addressing Diseases 130](#_Toc66530340)

[10. DIAGNOSTIC APPLICATIONS OF EXOSOMES 131](#_Toc66530341)

[10.1 Exosomal Proteins as Diagnostic Biomarkers 132](#_Toc66530342)

[10.2 Exosomal Nucleic Acids as Biomarkers 135](#_Toc66530343)

[10.2.1 Non-Coding RNAs in Exosomes as Biomarkers in Cancer 140](#_Toc66530344)

[10.3 Exosomes from other Biofluids as Cancer Biomarker 141](#_Toc66530345)

[10.4 Exosomes in Pregnancy Disorders 142](#_Toc66530346)

[10.5 Exosomes in Cardiovascular Diseases 144](#_Toc66530347)

[10.6 Exosomes in Organ Transplantation 146](#_Toc66530348)

[10.7 Published PubMed Articles on Exosome-Based Diagnosis 147](#_Toc66530349)

[11. THERAPEUTIC APPLICATIONS OF EXOSOMES 148](#_Toc66530350)

[11.1 Advantages of Exosomes as Therapeutics 150](#_Toc66530351)

[11.2 Therapeutic Exosome Platforms 150](#_Toc66530352)

[11.2.1 Naïve Exosome Therapeutics 150](#_Toc66530353)

[11.2.2 Engineered Exosome Therapeutics 151](#_Toc66530354)

[11.2.2.1 Passive Cargo Loading 151](#_Toc66530355)

[11.2.2.2 Active Cargo-Loading 152](#_Toc66530356)

[11.3 Examples of Drugs Encapsulated in Exosomes 155](#_Toc66530357)

[11.4 Preclinical Studies involving Exosomes with Therapeutics 157](#_Toc66530358)

[12. APPLICATIONS OF EXOSOMES IN VACCINE DEVELOPMENT 159](#_Toc66530359)

[12.1 Exosome-Based Immunotherapy in Animal Models 159](#_Toc66530360)

[12.2 Ongoing Clinical Trials involving Exosomes in Developing Vaccines 160](#_Toc66530361)

[13. EXOSOME RESEARCH TOOLS 161](#_Toc66530362)

[13.1 Exosome Capture/Quantification Kits 161](#_Toc66530363)

[13.2 Exosome-Associated RNA Extraction Kits 162](#_Toc66530364)

[13.3 Exosome Standards 163](#_Toc66530365)

[13.4 Immunoplates for Capture of Exosomes 163](#_Toc66530366)

[13.5 Immunobeads for Exosome Isolation 164](#_Toc66530367)

[13.6 Exosome Marker Antibodies 164](#_Toc66530368)

[14. EXOSOME MARKET ANALYSIS 165](#_Toc66530369)

[14.1 Market for Exosome Therapeutics 165](#_Toc66530370)

[14.2 Market for Exosome Diagnostics 167](#_Toc66530371)

[14.3 Market for Exosome Research Products 169](#_Toc66530372)

[15. PROFILES OF EXOPRENEURS 172](#_Toc66530373)

[15.1 101 Bio 174](#_Toc66530374)

[15.1.1 Exosome Services 174](#_Toc66530375)

[15.2 Abbexa, Ltd. 175](#_Toc66530376)

[15.3 Abnova 175](#_Toc66530377)

[15.4 Adipomics, Inc. 176](#_Toc66530378)

[15.5 Aegle Therapeutics 177](#_Toc66530379)

[15.5.1 Extracellular Vesicle Therapy 177](#_Toc66530380)

[15.6 Aethlon Medical, Inc. 178](#_Toc66530381)

[15.6.1 Hemopurifier in Cancer 178](#_Toc66530382)

[15.7 Aegle Therapeutics 179](#_Toc66530383)

[15.7.1 Aegle’s Platform Technology 179](#_Toc66530384)

[15.7.2 Epidermolysis Bullosa 179](#_Toc66530385)

[15.8 AgeX Therapeutics, Inc. 180](#_Toc66530386)

[15.8.1 PureStem Technology 180](#_Toc66530387)

[15.8.2 Induced Tissue Regeneration (iTR) 180](#_Toc66530388)

[15.8.3 UniverCyte 181](#_Toc66530389)

[15.9 Alexerion Biotech Corp. 182](#_Toc66530390)

[15.9.1 Drug Development 182](#_Toc66530391)

[15.9.2 EXOKIT 182](#_Toc66530392)

[15.10 AMS Biotechnology, Ltd. (AMSBIO) 183](#_Toc66530393)

[15.10.1 Products 183](#_Toc66530394)

[15.11 Anjarium Biosciences 184](#_Toc66530395)

[15.11.1 Anjarium’s Hybridosome Platform 184](#_Toc66530396)

[15.12 antibodies-online GmbH 184](#_Toc66530397)

[15.13 Aposcience AG 185](#_Toc66530398)

[15.13.1 Wound Healing 185](#_Toc66530399)

[15.13.2 Myocardial Infarction 185](#_Toc66530400)

[15.14 Aruna Bio 186](#_Toc66530401)

[15.14.1 AB126 186](#_Toc66530402)

[15.15 Avalon GloboCare Corp. 187](#_Toc66530403)

[15.15.1 Avalon’s Core Platforms 187](#_Toc66530404)

[15.16 Aviva Systems Biology 188](#_Toc66530405)

[15.17 Azymus Therapeutics 188](#_Toc66530406)

[15.17.1 AZ Platform 188](#_Toc66530407)

[15.18 BARD1 Life Sciences, Ltd. 189](#_Toc66530408)

[15.18.1 EXO-NET 189](#_Toc66530409)

[15.19 Beckman Coulter Life Sciences 190](#_Toc66530410)

[15.19.1 Optima XPN 190](#_Toc66530411)

[15.19.2 Vi-CELL BLU Cell Viability Analyzer 190](#_Toc66530412)

[15.19.3 SW 32 Swinging-Bucket Rotor 191](#_Toc66530413)

[15.19.4 CytoFLEX Flow Cytometer 191](#_Toc66530414)

[15.20 BioCat GmbH 191](#_Toc66530415)

[15.20.1 Exosome Purification Kits 191](#_Toc66530416)

[15.21 BioFluidica 192](#_Toc66530417)

[15.22 Biological Dynamics, Inc. 192](#_Toc66530418)

[15.22.1 Verita Isolation Platform 192](#_Toc66530419)

[15.23 Biorbyt, Ltd. 193](#_Toc66530420)

[15.24 BioRegenerative Sciences, Inc. 194](#_Toc66530421)

[15.24.1 SRM Technology 194](#_Toc66530422)

[15.25 Bio-Techne 195](#_Toc66530423)

[15.25.1 Products 195](#_Toc66530424)

[15.26 BioVision, Inc. 196](#_Toc66530425)

[15.27 BrainStorm Cell Therapeutics 197](#_Toc66530426)

[15.27.1 Exosome for COVID-19 197](#_Toc66530427)

[15.28 BreStem Therapeutics, Inc. 198](#_Toc66530428)

[15.29 Capricor Therapeutics 199](#_Toc66530429)

[15.29.1 Exosome Program 199](#_Toc66530430)

[15.30 CD Bioparticles 200](#_Toc66530431)

[15.30.1 Exosome Services 200](#_Toc66530432)

[15.31 Cellarcus Biosciences, Inc. 201](#_Toc66530433)

[15.31.1 vFC Vesicle Analysis Assays 201](#_Toc66530434)

[15.31.2 vTag Antibodies 201](#_Toc66530435)

[15.31.3 Vesicles and Vesicle Standards 202](#_Toc66530436)

[15.31.4 Vesicle Analysis Services 202](#_Toc66530437)

[15.31.5 Measuring EV Size and Concentration 202](#_Toc66530438)

[15.31.6 Quantifying Vesicle Cargo 203](#_Toc66530439)

[15.31.7 Custom Analysis Services 203](#_Toc66530440)

[15.32 Cell Care Therapeutics 203](#_Toc66530441)

[15.32.1 CCT-101 203](#_Toc66530442)

[15.33 Cell Factory BVBA/Esperite NV 204](#_Toc66530443)

[15.33.1 Exosome Projects 204](#_Toc66530444)

[15.34 Cell Guidance Systems, Ltd. 205](#_Toc66530445)

[15.34.1 Products for Exosome Research 205](#_Toc66530446)

[15.35 Ciloa 206](#_Toc66530447)

[15.35.1 Exosome Customization Technology 206](#_Toc66530448)

[15.36 Clara Biotech 207](#_Toc66530449)

[15.36.1 Clara’s Platform 207](#_Toc66530450)

[15.36.2 ExoRelease 207](#_Toc66530451)

[15.37 Codiak Biosciences 208](#_Toc66530452)

[15.37.1 engEX Platform 208](#_Toc66530453)

[15.37.2 exoASO-STAT6 208](#_Toc66530454)

[15.37.3 exoIL-12 209](#_Toc66530455)

[15.38 Creative Bioarray 209](#_Toc66530456)

[15.39 Creative Biolabs 210](#_Toc66530457)

[15.39.1 Products 210](#_Toc66530458)

[15.39.2 Services 210](#_Toc66530459)

[15.40 Creative Medical Technology Holdings, Inc. 211](#_Toc66530460)

[15.40.1 AmnioStem Stroke Therapy 211](#_Toc66530461)

[15.41 Creative Proteomics 212](#_Toc66530462)

[15.41.1 Exosome Proteomics Services 212](#_Toc66530463)

[15.42 Cusabio Technology LLC 213](#_Toc66530464)

[15.42.1 Exosome Isolation Kits 213](#_Toc66530465)

[15.43 Direct Biologics 214](#_Toc66530466)

[15.43.1 ExoFlo 214](#_Toc66530467)

[15.44 DLdevelop 214](#_Toc66530468)

[15.45 EVerZom 215](#_Toc66530469)

[15.45.1 Services 215](#_Toc66530470)

[15.46 Evomic Science, LLC 216](#_Toc66530471)

[15.46.1 ExoEZ Exosome Isolation Kit 216](#_Toc66530472)

[15.47 Evox Therapeutics, Ltd. 217](#_Toc66530473)

[15.47.1 Protein Therapeutics 217](#_Toc66530474)

[15.47.2 RNA Therapeutics 217](#_Toc66530475)

[15.48 ExBiome BV 218](#_Toc66530476)

[15.48.1 ExomiR Technology 218](#_Toc66530477)

[15.49 Exerkine Corp. 218](#_Toc66530478)

[15.50 ExoCan Healthcare Technologies, Pvt. Ltd. 219](#_Toc66530479)

[15.50.1 ExoEnrich Exosome Isolation Kit 219](#_Toc66530480)

[15.50.2 ExoEngineering 219](#_Toc66530481)

[15.51 ExoCoBio, Co., Ltd. 220](#_Toc66530482)

[15.51.1 Products 220](#_Toc66530483)

[15.52 Exogenus Therapeutics 221](#_Toc66530484)

[15.53 EXoPERT 222](#_Toc66530485)

[15.53.1 EXo-i 222](#_Toc66530486)

[15.54 Exopharm 223](#_Toc66530487)

[15.54.1 LEAP Technology 223](#_Toc66530488)

[15.54.2 Cevaris & Plexaris 223](#_Toc66530489)

[15.55 Exosome Diagnostics, Inc. 224](#_Toc66530490)

[15.55.1 ExoDx Prostate Test 224](#_Toc66530491)

[15.56 ExosomePlus 225](#_Toc66530492)

[15.57 Exosome Sciences 226](#_Toc66530493)

[15.57.1 TauSome Biomarker 226](#_Toc66530494)

[15.58 Exosomics S.p.A 227](#_Toc66530495)

[15.58.1 ExoRef 227](#_Toc66530496)

[15.58.2 SeleCTEV Enrichment Kits 227](#_Toc66530497)

[15.58.3 SoRTEV Enrichment Kit 227](#_Toc66530498)

[15.59 ExoVectory 228](#_Toc66530499)

[15.60 GenWay Biotech, Inc. 228](#_Toc66530500)

[15.61 Guardant Health, Inc. 229](#_Toc66530501)

[15.61.1 Guardant360 CDx 229](#_Toc66530502)

[15.62 HansaBioMed Life Sciences, Ltd. 230](#_Toc66530503)

[15.62.1 Products 230](#_Toc66530504)

[15.63 Hitachi Chemical Diagnostics, Inc. 231](#_Toc66530505)

[15.63.1 ExoComplete 231](#_Toc66530506)

[15.64 ILIAS Biologics, Inc. 232](#_Toc66530507)

[15.64.1 EXPLOR 232](#_Toc66530508)

[15.64.2 Exo-Target 232](#_Toc66530509)

[15.65 Innocan Pharma Corporation 233](#_Toc66530510)

[15.66 Innovex Therapeutics, S.L. 234](#_Toc66530511)

[15.66.1 Research & Development 234](#_Toc66530512)

[15.67 Invent Biotechnologies, Inc. 235](#_Toc66530513)

[15.68 Invitrx Therapeutics 235](#_Toc66530514)

[15.68.1 Reluma 235](#_Toc66530515)

[15.69 Izon Science, Ltd. 236](#_Toc66530516)

[15.69.1 qEV Exosome Isolation 236](#_Toc66530517)

[15.70 Kimera Labs, Inc. 236](#_Toc66530518)

[15.71 Leading Biology, Inc. 237](#_Toc66530519)

[15.72 LifeSpan BioSciences, Inc. 237](#_Toc66530520)

[15.73 Lonza Group Ltd. 238](#_Toc66530521)

[15.73.1 Exosome Service 238](#_Toc66530522)

[15.74 Mantra Bio 239](#_Toc66530523)

[15.74.1 Partnering 239](#_Toc66530524)

[15.75 MDimune 240](#_Toc66530525)

[15.75.1 BioDrone Technology 240](#_Toc66530526)

[15.76 Miltenyi Biotec B.V. & Co. KG 241](#_Toc66530527)

[15.76.1 qEV Exosome Isolation Kit 241](#_Toc66530528)

[15.77 miR Scientific 242](#_Toc66530529)

[15.77.1 Prostate Cancer Test 242](#_Toc66530530)

[15.78 Mursla, Ltd. 242](#_Toc66530531)

[15.79 MyBioSource, Inc. 243](#_Toc66530532)

[15.80 NanoSomix, Inc. 244](#_Toc66530533)

[15.80.1 Technology 244](#_Toc66530534)

[15.81 NanoView Biosciences 245](#_Toc66530535)

[15.81.1 ExoView R 100 245](#_Toc66530536)

[15.81.2 ExoView Tetraspanin Kits 245](#_Toc66530537)

[15.82 NeurExo Sciences 246](#_Toc66530538)

[15.83 New England Peptide, Inc. 247](#_Toc66530539)

[15.83.1 ME-Kit for Exosome Isolation 247](#_Toc66530540)

[15.84 Norgen Biotek Corp. 248](#_Toc66530541)

[15.84.1 Services 248](#_Toc66530542)

[15.85 Novus Biologicals, LLC 249](#_Toc66530543)

[15.85.1 Exosomes Research Tools 249](#_Toc66530544)

[15.86 nRichDx, Inc. 250](#_Toc66530545)

[15.87 Oasis Diagnostics Corp. 251](#_Toc66530546)

[15.87.1 Pure.SAL 251](#_Toc66530547)

[15.88 OmniSpirant Limited 252](#_Toc66530548)

[15.88.1 Technology 252](#_Toc66530549)

[15.89 OriGene Technologies, Inc. 253](#_Toc66530550)

[15.90 Paracrine Therapeutics, Pvt. Ltd. 253](#_Toc66530551)

[15.91 QIAGEN 254](#_Toc66530552)

[15.91.1 ExoEasy Maxi Kit 254](#_Toc66530553)

[15.91.2 miRCURY Exosome Kits 254](#_Toc66530554)

[15.92 ReNeuron 255](#_Toc66530555)

[15.92.1 Exosome Platform 255](#_Toc66530556)

[15.93 RoosterBio, Inc. 256](#_Toc66530557)

[15.93.1 RoosterCollect-EV 256](#_Toc66530558)

[15.94 Stemcell Medicine, Ltd. 257](#_Toc66530559)

[15.95 System Biosciences, LLC 258](#_Toc66530560)

[15.95.1 Exosome Research Products 258](#_Toc66530561)

[15.95.2 Exosome Research Services 258](#_Toc66530562)

[15.96 Tavec Pharma 259](#_Toc66530563)

[15.96.1 Technology 259](#_Toc66530564)

[15.97 Theoria Science, Inc. 260](#_Toc66530565)

[15.97.1 Technology: ExoScreen 260](#_Toc66530566)

[15.98 Thermo Fisher Scientific 261](#_Toc66530567)

[15.98.1 Exosome Products for Testing and Research 261](#_Toc66530568)

[15.99 TransGen Biotech, Co., Ltd. 262](#_Toc66530569)

[15.100 TriArm Therapeutics, Co., Ltd. 262](#_Toc66530570)

[15.100.1 Exosome Engineering Platform 262](#_Toc66530571)

[15.101 United Therapeutics Corp. 263](#_Toc66530572)

[15.101.1 Unexisome 263](#_Toc66530573)

[15.102 Versatope Therapeutics 264](#_Toc66530574)

[15.102.1 VT-105 264](#_Toc66530575)

[15.103 Vesigen Therapeutics, Inc. 265](#_Toc66530576)

[15.103.1 Technology 265](#_Toc66530577)

[15.104 VivaZome Therapeutics, Pvt. Ltd. 266](#_Toc66530578)

[15.105 Xollent Biotech 267](#_Toc66530579)

[15.105.1 Pipeline 267](#_Toc66530580)

[15.106 XOStem, Inc. 268](#_Toc66530581)

[15.107 YMIR Genomics LLC 269](#_Toc66530582)

[15.107.1 Urine Biomarker Isolation Method 269](#_Toc66530583)

[15.107.2 Ymatrix 269](#_Toc66530584)

**INDEX OF FIGURES**

[FIGURE 2.1: Exosome Formation 21](#_Toc66530585)

[FIGURE 2.2: Exosome Uptake by Target Cells 22](#_Toc66530586)

[FIGURE 2.3: Structure of an Exosome 23](#_Toc66530587)

[FIGURE 2.4: Schematic of Membrane and Lumen Components of Exosomes 28](#_Toc66530588)

[FIGURE 2.5: Diagrammatic Representation of Developing Engineered Exosomes 29](#_Toc66530589)

[FIGURE 2.6: Shares of MSCs from Sources used in Preclinical Studies for Exosomes 32](#_Toc66530590)

[FIGURE 3.1: Most Common Exosome Isolation Methods 38](#_Toc66530591)

[FIGURE 3.2: Exosome Labeling Methods in Exosome Biodistribution Analysis 42](#_Toc66530592)

[FIGURE 3.3: Fluorescent Dyes used in Labeling Exosomes 43](#_Toc66530593)

[FIGURE 3.4: Common Methods to Remove Unlabelled Probes 43](#_Toc66530594)

[FIGURE 3.5: Determination of Exosome Dose for Biodistribution Analysis 44](#_Toc66530595)

[FIGURE 3.6: Routes of Exosome Administration 45](#_Toc66530596)

[FIGURE 3.7: Tested and Non-Tested Exosomes in Research 45](#_Toc66530597)

[FIGURE 3.8: Number of PubMed Publications on Exosomes, 2020-2020 46](#_Toc66530598)

[FIGURE 3.9: Top Five Countries with Largest Number of Publications 47](#_Toc66530599)

[FIGURE 3.10: No. of PubMed Publications on Exosomes and DNA Diagnosis, 2010-2020 48](#_Toc66530600)

[FIGURE 3.11: No. of PubMed Publications on Exosomes and RNA Diagnosis, 2010-2020 49](#_Toc66530601)

[FIGURE 3.12: No. of PubMed Publications on Exosomes and Protein Diagnosis, 2010-2020 50](#_Toc66530602)

[FIGURE 3.13: Number of PubMed Publications on Exosomes from Stem Cells, 2010-2020 51](#_Toc66530603)

[FIGURE 3.14: Number of PubMed Publications on Exosomes as Diagnostics, 2000-2020 52](#_Toc66530604)

[FIGURE 3.15: Number of PubMed Publications on Exosomes as Therapeutics, 2000-2020 53](#_Toc66530605)

[FIGURE 3.16: No. of PubMed Publications on Exosomes for Cancer Diagnosis, 2010-2020 54](#_Toc66530606)

[FIGURE 3.17: PubMed Publications for Pregnancy Disorders Diagnosis, 2010-2020 55](#_Toc66530607)

[FIGURE 4.1: Share of Exosome Clinical Trials by Geography 61](#_Toc66530608)

[FIGURE 5.1: Schematic Models of Continuous Exosome Manufacturing Approaches 67](#_Toc66530609)

[FIGURE 5.2: Upstream Cell Line Production Methods 68](#_Toc66530610)

[FIGURE 5.3: Downstream Exosome Purification Methods 69](#_Toc66530611)

[FIGURE 6.1: Diagnostic Applications of Exosomes 73](#_Toc66530612)

[FIGURE 6.2: The Two Engineering Approaches to Produce Designer Exosomes 86](#_Toc66530613)

[FIGURE 6.3: Countries Having Major Shares in Exosome Patents 98](#_Toc66530614)

[FIGURE 7.1: Diagrammatic Representation of Differential Ultracentrifugation 101](#_Toc66530615)

[FIGURE 7.2: Diagrammatic Representation of Gradient Density Ultracentrifugation 101](#_Toc66530616)

[FIGURE 7.3: Diagrammatic Representation of Ultrafiltration and Sequential Ultrafiltration 102](#_Toc66530617)

[FIGURE 7.4: Diagrammatic Representation of Size-Exclusion Chromatography 103](#_Toc66530618)

[FIGURE 7.5: Diagrammatic Representation of Polymer Precipitation 103](#_Toc66530619)

[FIGURE 7.6: Diagrammatic Representation of Immunoaffinity Capture 104](#_Toc66530620)

[FIGURE 7.7: Diagrammatic Representation of Microfluidics-Based Technique 105](#_Toc66530621)

[FIGURE 7.8: Illustration of Conventional and Biofluidid-Based Isolation Methods 107](#_Toc66530622)

[FIGURE 7.9: Comparative Yield of Exosomes by Isolation Methods 109](#_Toc66530623)

[FIGURE 7.10: Relative Viability of Exosomes by Isolation Method 110](#_Toc66530624)

[FIGURE 8.1: Exosomes with Loaded Therapeutics in the Lumen and Surface Display 120](#_Toc66530625)

[FIGURE 8.2: Parental Cell-Based Exosome Engineering 121](#_Toc66530626)

[FIGURE 8.3: Direct or Post-Isolation Exosome Engineering Approach 122](#_Toc66530627)

[FIGURE 9.1: Therapeutic Effects of MSC-Derived Exosomes in Preclinical Studies 125](#_Toc66530628)

[FIGURE 10.1: Published PubMed Articles on Exosome-Based Diagnosis 147](#_Toc66530629)

[FIGURE 11.1: Different Approaches for Loading Drugs into Exosomes 148](#_Toc66530630)

[FIGURE 11.2: Sketch of an Exosome Carrying Not-Fully Identified Functional Molecules 151](#_Toc66530631)

[FIGURE 11.3: Passive Cargo-Loading 152](#_Toc66530632)

[FIGURE 11.4: Active Cargo-Loading with Anchored Cargo 153](#_Toc66530633)

[FIGURE 11.5: Active Cargo-Loading with Free-Cargo 153](#_Toc66530634)

[FIGURE 14.1: Market for Exosome Therapeutics and Diagnostics by Region, 2020-2028 168](#_Toc66530635)

[FIGURE 14.2: Market Share of Exosome Isolation Methods 169](#_Toc66530636)

[FIGURE 14.3: Percent Utilization of Research Tools used on Captured Exosomes 170](#_Toc66530637)

[FIGURE 14.4: Market for Exosome-Based Research Products by Region, 2020-2028 171](#_Toc66530638)

**INDEX OF TABLES**

[TABLE 2.1: Molecular Content of Exosomes 24](#_Toc66530744)

[TABLE 2.2: Common Protein Components of Exosomes 25](#_Toc66530745)

[TABLE 2.3: Common Lipid Components of Exosomes 26](#_Toc66530746)

[TABLE 2.4: Nucleic Acids Present in Tumor-derived Exosomes 27](#_Toc66530747)

[TABLE 2.5: Methods of Developing Engineered Exosomes 29](#_Toc66530748)

[TABLE 2.6: Differences between Exosome Therapy and Cell Therapy 31](#_Toc66530749)

[TABLE 2.7: Comparative Studies using Exosomes from different MSCs 33](#_Toc66530750)

[TABLE 3.1: Comparison of MISEV2018 and MFDS2018 Guidelines 39](#_Toc66530751)

[TABLE 3.2: Comparison of Imaging Modalities used in Exosome Research 40](#_Toc66530752)

[TABLE 3.3: Comparison of Exosome Labeling Methods 41](#_Toc66530753)

[TABLE 4.1: Recruitment Status for Exosome-based Clinical Trials 58](#_Toc66530754)

[TABLE 4.2: Study Types of Ongoing Exosome-Based Clinical Trials 58](#_Toc66530755)

[TABLE 4.3: Study Phase for Exosome-based Clinical Trials 59](#_Toc66530756)

[TABLE 4.4: Phase III & Phase IV Exosome Studies in Clinical Trials 60](#_Toc66530757)

[TABLE 4.5: Funder Types of Exosome-based Clinical Trials 60](#_Toc66530758)

[TABLE 4.6: Exosome-based Clinical Trials by Application 62](#_Toc66530759)

[TABLE 4.7: Examples of Clinical Trials involving MSC-Derived Exosomes 63](#_Toc66530760)

[TABLE 4.8: NIH Clinical Trials involving Exosomes as Therapeutic Interventions 64](#_Toc66530761)

[TABLE 5.1: List of Companies offering Exosome Services and Products 69](#_Toc66530762)

[TABLE 5.1: (CONTINUED) 70](#_Toc66530763)

[TABLE 6.1: Companies Developing Exosome-Based Diagnostics 75](#_Toc66530764)

[TABLE 6.2: Select Clinical Trials Focusing on Evaluating Exosome Diagnostics 75](#_Toc66530765)

[TABLE 6.3: List of Commercial Companies that use Exosomes for Therapies 76](#_Toc66530766)

[TABLE 6.4: Promising Exosome-based Therapeutic Candidates 77](#_Toc66530767)

[TABLE 6.5: A Short List of Diseases addressed by Exosome Therapeutics 82](#_Toc66530768)

[TABLE 6.6: Select Exosome-Based Clinical Trials from 2010 to 2020 84](#_Toc66530769)

[TABLE 6.6: (CONTINUED) 85](#_Toc66530770)

[TABLE 6.7: List of NIH Funded Exosome Research Projects in 2021 87](#_Toc66530771)

[TABLE 6.7: (CONTINUED) 88](#_Toc66530772)

[TABLE 6.8: Deals and Fund Raising in Exosome Space 92](#_Toc66530773)

[TABLE 6.9: Categories of Exosome Companies 96](#_Toc66530774)

[TABLE 6.10: Major Companies Holding Exosome Patents 97](#_Toc66530775)

[TABLE 7.1: Current Strategies for Exosome Isolation 100](#_Toc66530776)

[TABLE 7.2: The Active and Passive Methods of Microfluidics Platforms 105](#_Toc66530777)

[TABLE 7.3: Microfluidics-Based Exosome Isolation Techniques 106](#_Toc66530778)

[TABLE 7.4: Commercially Available Exosome Kits 108](#_Toc66530779)

[TABLE 7.5: Summary of Different Exosomes Isolation Methods 111](#_Toc66530780)

[TABLE 7.6: Approaches for Exosome Analysis of Gene and Protein Biomarkers 114](#_Toc66530781)

[TABLE 7.7: Emerging Optical Exosome Analysis Techniques 114](#_Toc66530782)

[TABLE 7.7: (CONTINUED) 115](#_Toc66530783)

[TABLE 7.7: (CONTINUED) 116](#_Toc66530784)

[TABLE 7.7: (CONTINUED) 117](#_Toc66530785)

[TABLE 7.7: (CONTINUED) 118](#_Toc66530786)

[TABLE 7.8: Electrochemical and Electromechanical Approaches for Exosome Analysis 119](#_Toc66530787)

[TABLE 8.1: Examples of Loaded and Displayed Molecules in Direct Exosome Engineering 122](#_Toc66530788)

[TABLE 8.2: Targeting Moieties used for Developing Targeted Designer Exosomes 123](#_Toc66530789)

[TABLE 9.1: Select Preclinical Studies Addressing Cardiovascular Diseases 126](#_Toc66530790)

[TABLE 9.2: Select Preclinical Studies Addressing Kidney Diseases 127](#_Toc66530791)

[TABLE 9.3: Select Preclinical Studies Addressing Liver Diseases 128](#_Toc66530792)

[TABLE 9.4: Select Preclinical Studies Addressing Wound Healing 129](#_Toc66530793)

[TABLE 9.5: MSC-Derived Exosomes in Clinical Trials for Regenerative Medicines 130](#_Toc66530794)

[TABLE 10.1: Exosomal Cargo as Biomarkers for Disease Diagnosis 131](#_Toc66530795)

[TABLE 10.1: (CONTINUED) 132](#_Toc66530796)

[TABLE 10.2: Exosomal Proteins in Different Cancers 132](#_Toc66530797)

[TABLE 10.2: (CONTINUED) 133](#_Toc66530798)

[TABLE 10.2: (CONTINUED) 134](#_Toc66530799)

[TABLE 10.2: (CONTINUED) 135](#_Toc66530800)

[TABLE 10.3: Types of RNA as Biomarker for Different Cancers 136](#_Toc66530801)

[TABLE 10.3: (CONTINUED) 137](#_Toc66530802)

[TABLE 10.3: (CONTINUED) 138](#_Toc66530803)

[TABLE 10.3: (CONTINUED) 139](#_Toc66530804)

[TABLE 10.4: Non-Coding RNAs in Exosomes as Biomarkers in Cancer 140](#_Toc66530805)

[TABLE 10.5: Exosomal Cancer Biomarkers from other Body Fluids 141](#_Toc66530806)

[TABLE 10.6: Target Molecules of Exosomes for Diagnosis in Pregnancy Disorders 142](#_Toc66530807)

[TABLE 10.6: (CONTINUED) 143](#_Toc66530808)

[TABLE 10.7: Target Molecules of Exosomes for Diagnosis in Cardiovascular Diseases 144](#_Toc66530809)

[TABLE 10.7: (CONTINUED) 145](#_Toc66530810)

[TABLE 10.8: Target Molecules of Exosomes for Diagnosis in Organ Transplantations 146](#_Toc66530811)

[TABLE 11.1: List of Commercial Companies that use Exosomes for Therapies 149](#_Toc66530812)

[TABLE 11.2: Summary of Exosome Engineering Methods for Cargo Delivery 154](#_Toc66530813)

[TABLE 11.3: Examples of Drugs Encapsulated in Exosomes 156](#_Toc66530814)

[TABLE 11.4: Preclinical Studies involving Exosomes loaded with Therapeutics 157](#_Toc66530815)

[TABLE 11.4: (CONTINUED) 158](#_Toc66530816)

[TABLE 12.1: The Potential of as a New Approach to Cancer Vaccines in Animal Models 159](#_Toc66530817)

[TABLE 12.2: Ongoing Clinical Trials of Exosome-Based Cancer Immunotherapy 160](#_Toc66530818)

[TABLE 13.1: Commercially available Exosome Isolation Kits 161](#_Toc66530819)

[TABLE 13.2: Commercially available Exosome Isolation Kits 162](#_Toc66530820)

[TABLE 13.3: Exosome-Associated RNA Isolation Kits 162](#_Toc66530821)

[TABLE 13.4: Commercially Available Exosome Standards 163](#_Toc66530822)

[TABLE 13.5: Commercially Available Immunoplates for Exosome Capture 163](#_Toc66530823)

[TABLE 13.6: Commercially Available Immunobeads for Exosome Isolation 164](#_Toc66530824)

[TABLE 13.7: Commercially Available Exosome Marker Antibodies 164](#_Toc66530825)

[TABLE 14.1: Market for Exosome Therapeutics and Diagnostics by Region, 2020-2028 168](#_Toc66530826)

[TABLE 14.2: Market for Exosome-Based Research Products by Region, 2020-2028 171](#_Toc66530827)

[TABLE 15.1: Alexerion’s Exosome-Based Pipeline 182](#_Toc66530828)

[TABLE 15.3: Xollent’s Pipeline of Exosome-Based candidates 267](#_Toc66530829)

[TABLE 15.4: All Known Exosome Companies Worldwide 270](#_Toc66530830)

**About BioInformant**

BioInformant is the first and only market research firm to specialize in the stem cell industry.

BioInformant research has been cited by prominent news outlets that include the Wall Street Journal, Nature Biotechnology, Xconomy, and Vogue Magazine.

Serving Fortune 500 companies that include Pfizer, Goldman Sachs, and GE Healthcare, BioInformant is your global leader in stem cell industry data.